vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Enphase Energy (ENPH). Click either name above to swap in a different company.
Enphase Energy is the larger business by last-quarter revenue ($282.9M vs $247.1M, roughly 1.1× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs -2.6%, a 13.7% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs -20.6%). Enphase Energy produced more free cash flow last quarter ($83.0M vs $29.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs -3.4%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Enphase Energy, Inc. is an American energy technology company headquartered in Fremont, California, that develops and manufactures solar micro-inverters, battery energy storage, and EV charging stations primarily for residential customers. Enphase was established in 2006 and is the first company to successfully commercialize solar micro-inverters, which convert the direct current (DC) power generated by solar panels into grid-compatible alternating current (AC) for use or export.
ANIP vs ENPH — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $282.9M |
| Net Profit | $27.5M | $-7.4M |
| Gross Margin | — | 35.5% |
| Operating Margin | 14.1% | 54.0% |
| Net Margin | 11.1% | -2.6% |
| Revenue YoY | 29.6% | -20.6% |
| Net Profit YoY | 367.5% | -124.9% |
| EPS (diluted) | $1.14 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $282.9M | ||
| Q4 25 | $247.1M | $343.3M | ||
| Q3 25 | $227.8M | $410.4M | ||
| Q2 25 | $211.4M | $363.2M | ||
| Q1 25 | $197.1M | $356.1M | ||
| Q4 24 | $190.6M | $382.7M | ||
| Q3 24 | $148.3M | $380.9M | ||
| Q2 24 | $138.0M | $303.5M |
| Q1 26 | — | $-7.4M | ||
| Q4 25 | $27.5M | $38.7M | ||
| Q3 25 | $26.6M | $66.6M | ||
| Q2 25 | $8.5M | $37.1M | ||
| Q1 25 | $15.7M | $29.7M | ||
| Q4 24 | $-10.3M | $62.2M | ||
| Q3 24 | $-24.2M | $45.8M | ||
| Q2 24 | $-2.3M | $10.8M |
| Q1 26 | — | 35.5% | ||
| Q4 25 | — | 44.3% | ||
| Q3 25 | — | 47.8% | ||
| Q2 25 | — | 46.9% | ||
| Q1 25 | — | 47.2% | ||
| Q4 24 | — | 51.8% | ||
| Q3 24 | — | 46.8% | ||
| Q2 24 | — | 45.2% |
| Q1 26 | — | 54.0% | ||
| Q4 25 | 14.1% | 6.5% | ||
| Q3 25 | 15.9% | 16.1% | ||
| Q2 25 | 6.6% | 10.2% | ||
| Q1 25 | 13.3% | 9.0% | ||
| Q4 24 | -2.3% | 14.3% | ||
| Q3 24 | -13.8% | 13.1% | ||
| Q2 24 | 3.7% | 0.6% |
| Q1 26 | — | -2.6% | ||
| Q4 25 | 11.1% | 11.3% | ||
| Q3 25 | 11.7% | 16.2% | ||
| Q2 25 | 4.0% | 10.2% | ||
| Q1 25 | 8.0% | 8.3% | ||
| Q4 24 | -5.4% | 16.2% | ||
| Q3 24 | -16.3% | 12.0% | ||
| Q2 24 | -1.7% | 3.6% |
| Q1 26 | — | $-0.06 | ||
| Q4 25 | $1.14 | $0.29 | ||
| Q3 25 | $1.13 | $0.50 | ||
| Q2 25 | $0.36 | $0.28 | ||
| Q1 25 | $0.69 | $0.22 | ||
| Q4 24 | $-0.45 | $0.46 | ||
| Q3 24 | $-1.27 | $0.33 | ||
| Q2 24 | $-0.14 | $0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $497.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $1.1B |
| Total Assets | $1.4B | $2.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $497.5M | ||
| Q4 25 | $285.6M | $1.5B | ||
| Q3 25 | $262.6M | $1.5B | ||
| Q2 25 | $217.8M | $1.5B | ||
| Q1 25 | $149.8M | $1.5B | ||
| Q4 24 | $144.9M | $1.6B | ||
| Q3 24 | $145.0M | $1.8B | ||
| Q2 24 | $240.1M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.3B | ||
| Q2 24 | — | $1.3B |
| Q1 26 | — | $1.1B | ||
| Q4 25 | $540.7M | $1.1B | ||
| Q3 25 | $505.8M | $995.0M | ||
| Q2 25 | $436.8M | $880.6M | ||
| Q1 25 | $418.6M | $810.7M | ||
| Q4 24 | $403.7M | $833.0M | ||
| Q3 24 | $405.9M | $931.4M | ||
| Q2 24 | $455.8M | $884.5M |
| Q1 26 | — | $2.7B | ||
| Q4 25 | $1.4B | $3.5B | ||
| Q3 25 | $1.4B | $3.3B | ||
| Q2 25 | $1.3B | $3.2B | ||
| Q1 25 | $1.3B | $3.1B | ||
| Q4 24 | $1.3B | $3.2B | ||
| Q3 24 | $1.3B | $3.3B | ||
| Q2 24 | $920.8M | $3.2B |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.11× | ||
| Q3 25 | — | 1.21× | ||
| Q2 25 | — | 1.37× | ||
| Q1 25 | — | 1.48× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | — | 1.40× | ||
| Q2 24 | — | 1.47× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $102.9M |
| Free Cash FlowOCF − Capex | $29.1M | $83.0M |
| FCF MarginFCF / Revenue | 11.8% | 29.3% |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $145.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $102.9M | ||
| Q4 25 | $30.4M | $47.6M | ||
| Q3 25 | $44.1M | $13.9M | ||
| Q2 25 | $75.8M | $26.6M | ||
| Q1 25 | $35.0M | $48.4M | ||
| Q4 24 | $15.9M | $167.3M | ||
| Q3 24 | $12.5M | $170.1M | ||
| Q2 24 | $17.4M | $127.1M |
| Q1 26 | — | $83.0M | ||
| Q4 25 | $29.1M | $37.8M | ||
| Q3 25 | $38.0M | $5.9M | ||
| Q2 25 | $71.8M | $18.4M | ||
| Q1 25 | $32.5M | $33.8M | ||
| Q4 24 | $13.5M | $159.2M | ||
| Q3 24 | $7.7M | $161.6M | ||
| Q2 24 | $13.0M | $117.4M |
| Q1 26 | — | 29.3% | ||
| Q4 25 | 11.8% | 11.0% | ||
| Q3 25 | 16.7% | 1.4% | ||
| Q2 25 | 34.0% | 5.1% | ||
| Q1 25 | 16.5% | 9.5% | ||
| Q4 24 | 7.1% | 41.6% | ||
| Q3 24 | 5.2% | 42.4% | ||
| Q2 24 | 9.4% | 38.7% |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 2.8% | ||
| Q3 25 | 2.7% | 2.0% | ||
| Q2 25 | 1.9% | 2.3% | ||
| Q1 25 | 1.3% | 4.1% | ||
| Q4 24 | 1.3% | 2.1% | ||
| Q3 24 | 3.2% | 2.2% | ||
| Q2 24 | 3.2% | 3.2% |
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | 1.23× | ||
| Q3 25 | 1.66× | 0.21× | ||
| Q2 25 | 8.87× | 0.72× | ||
| Q1 25 | 2.23× | 1.63× | ||
| Q4 24 | — | 2.69× | ||
| Q3 24 | — | 3.72× | ||
| Q2 24 | — | 11.73× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
ENPH
Segment breakdown not available.
